Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Receivables (2020 - 2025)

Cyclerion Therapeutics has reported Receivables over the past 6 years, most recently at $100000.0 for Q3 2025.

  • Quarterly results put Receivables at $100000.0 for Q3 2025, up 127.27% from a year ago — trailing twelve months through Sep 2025 was $100000.0 (up 127.27% YoY), and the annual figure for FY2024 was $556000.0, changed.
  • Receivables for Q3 2025 was $100000.0 at Cyclerion Therapeutics, down from $525000.0 in the prior quarter.
  • Over the last five years, Receivables for CYCN hit a ceiling of $581000.0 in Q1 2025 and a floor of $44000.0 in Q3 2024.
  • Median Receivables over the past 5 years was $192500.0 (2021), compared with a mean of $244750.0.
  • Biggest five-year swings in Receivables: plummeted 57.71% in 2023 and later skyrocketed 127.27% in 2025.
  • Cyclerion Therapeutics' Receivables stood at $100000.0 in 2021, then decreased by 4.0% to $96000.0 in 2022, then changed by 0.0% to $96000.0 in 2023, then skyrocketed by 479.17% to $556000.0 in 2024, then tumbled by 82.01% to $100000.0 in 2025.
  • The last three reported values for Receivables were $100000.0 (Q3 2025), $525000.0 (Q2 2025), and $581000.0 (Q1 2025) per Business Quant data.